When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices
Most efficacy studies can be initiated within two business days.
We love our clients! We are flexible and easy to work with. And we take a personal interest in our clients' studies.
Founded in 2013, Rincon Bio is a pre-clinical CRO focusing on in vivo cancer efficacy studies, both allogeneic (human cell models) and syngeneic (immunotherapy models).
The staff at Rincon Bio have performed hundreds of efficacy studies for pharma researchers across the United States, Europe, and Asia - both in industry and in academia.
We've worked in the world of pharma, which gives us a unique perspective as a CRO. We understand that consistent communication is key, flexibility is crucial, and that time is of the essence - which is why we can initiate most studies within two business days.
Rincon Bio is a US-based organization, born from a desire to provide domestic quality at competitive prices.
If you decide to run your study at Rincon Bio, the process will be easy, streamlined, and pleasant.
MEET OUR SCIENTIFIC DIRECTOR
Bret Stephens, PhD
Dr. Stephens has a broad in vivo biology background that comes from twenty years of involvement in cancer drug discovery in both academic and pharmaceutical industry settings.
Dr. Stephens received his PhD degree in Molecular Biology from the University of Arizona.
Previous to joining Rincon Bio, Dr. Stephens worked at Tolero Pharmaceuticals, Huntsman Cancer Institute (University of Utah), and the BioDesign Institute (Arizona State University), where he focused on cancer small molecule drug development.